Evidence map›Paper›PMID 39598184›Full record

ReviewLife (Basel, Switzerland)2024

Novel Approaches for the Early Detection of Glaucoma Using Artificial Intelligence.

Marco Zeppieri, Lorenzo Gardini, Carola Culiersi, Luigi Fontana, Mutali Musa, Fabiana D'Esposito, Pier Luigi Surico, Caterina Gagliano, Francesco Saverio Sorrentino

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Meeting Challenges in the Diagnosis and Treatment of Glaucoma.Bioengineering (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marco ZeppieriDepartment of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.ORCID 0000-0003-0999-5545
Lorenzo GardiniUnit of Ophthalmology, Department of Surgical Sciences, Ospedale Maggiore, 40100 Bologna, Italy.
Carola CuliersiUnit of Ophthalmology, Department of Surgical Sciences, Ospedale Maggiore, 40100 Bologna, Italy.ORCID 0000-0003-3221-3791
Luigi FontanaOphthalmology Unit, Department of Surgical Sciences, IRCCS Azienda Ospedaliero, Alma Mater Studiorum University of Bologna, 40100 Bologna, Italy.
Mutali MusaDepartment of Optometry, University of Benin, Benin City 300238, Nigeria.ORCID 0000-0001-7486-8361
Fabiana D'EspositoImperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, 153-173 Marylebone Rd, London NW15QH, UK.ORCID 0000-0002-7938-876X
Pier Luigi SuricoSchepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-7721-4694
Caterina GaglianoDepartment of Medicine and Surgery, University of Enna "Kore", Piazza dell'Università, 94100 Enna, Italy.ORCID 0000-0001-8424-0068
Francesco Saverio SorrentinoUnit of Ophthalmology, Department of Surgical Sciences, Ospedale Maggiore, 40100 Bologna, Italy.ORCID 0000-0002-7691-8980

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIf left untreated, glaucoma-the second most common cause of blindness worldwide-causes irreversible visual loss due to a gradual neurodegeneration of the retinal ganglion cells. Conventional techniques for identifying glaucoma, like optical coherence tomography (OCT) and visual field exams, are frequently laborious and dependent on subjective interpretation. Through the fast and accurate analysis of massive amounts of imaging data, artificial intelligence (AI), in particular machine learning (ML) and deep learning (DL), has emerged as a promising method to improve the early detection and management of glaucoma.

aimsThe purpose of this study is to examine the current uses of AI in the early diagnosis, treatment, and detection of glaucoma while highlighting the advantages and drawbacks of different AI models and algorithms. In addition, it aims to determine how AI technologies might transform glaucoma treatment and suggest future lines of inquiry for this area of study.

methodsA thorough search of databases, including Web of Science, PubMed, and Scopus, was carried out to find pertinent papers released until August 2024. The inclusion criteria were limited to research published in English in peer-reviewed publications that used AI, ML, or DL to diagnose or treat glaucoma in human subjects. Articles were chosen and vetted according to their quality, contribution to the field, and relevancy.

resultsConvolutional neural networks (CNNs) and other deep learning algorithms are among the AI models included in this paper that have been shown to have excellent sensitivity and specificity in identifying glaucomatous alterations in fundus photos, OCT scans, and visual field tests. By automating standard screening procedures, these models have demonstrated promise in distinguishing between glaucomatous and healthy eyes, forecasting the course of the disease, and possibly lessening the workload of physicians. Nonetheless, several significant obstacles remain, such as the requirement for various training datasets, outside validation, decision-making transparency, and handling moral and legal issues.

conclusionsArtificial intelligence (AI) holds great promise for improving the diagnosis and treatment of glaucoma by facilitating prompt and precise interpretation of imaging data and assisting in clinical decision making. To guarantee wider accessibility and better patient results, future research should create strong generalizable AI models validated in various populations, address ethical and legal matters, and incorporate AI into clinical practice.

Indexed as

artificial intelligencedeep learningglaucomamachine learningoptic disc neuropathyvisual field

Identifiers

PMID39598184
PMCPMC11595922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.